At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
PF-06700841drug
Likely dose
PF-06700841 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN LABEL, SINGLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-06700841 IN PARTICIPANTS WITH RENAL IMPAIRMENT AND IN HEALTHY PARTICIPANTS WITH NORMAL RENAL FUNCTION
In Brief
A Phase 1 clinical trial evaluating PF-06700841 for Healthy Volunteer and Renal Impairment. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer, Renal Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJul 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedFeb 7, 2020
Enrollment StartJul 3, 2020
Primary CompletionMay 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.4 years ago
Interventions
PF-06700841drug
A single dose of 30 mg PF-06700841 will be administered on Day 1